| Literature DB >> 30718106 |
Tânia Melo1, Javier-Fernando Montero-Bullón2, Pedro Domingues3, M Rosário Domingues4.
Abstract
Nitro-fatty acids (NO2-FA) undergo reversible Michael adduction reactions with cysteine and histidine residues leading to the post-translational modification (PTM) of proteins. This electrophilic character of NO2-FA is strictly related to their biological roles. The NO2-FA-induced PTM of signaling proteins can lead to modifications in protein structure, function, and subcellular localization. The nitro lipid-protein adducts trigger a series of downstream signaling events that culminates with anti-inflammatory, anti-hypertensive, and cytoprotective effects mediated by NO2-FA. These lipoxidation adducts have been detected and characterized both in model systems and in biological samples by using mass spectrometry (MS)-based approaches. These MS approaches allow to unequivocally identify the adduct together with the targeted residue of modification. The identification of the modified proteins allows inferring on the possible impact of the NO2-FA-induced modification. This review will focus on MS-based approaches as valuable tools to identify NO2-FA-protein adducts and to unveil the biological effect of this lipoxidation adducts.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30718106 PMCID: PMC6859590 DOI: 10.1016/j.redox.2019.101106
Source DB: PubMed Journal: Redox Biol ISSN: 2213-2317 Impact factor: 11.799
Fig. 1Schematic representation of nitrated lipids pathways: from their generation to their biological effect.
Fig. 2Representative mechanisms of nitro-fatty acid (NO2-FA) formation. Radical-induced nitration of unsaturated fatty acids by nitrogen dioxide (•NO2) yields a β-nitroalkyl radical that can further react with other •NO2 generating the nitronitrite intermediates. Further loss of nitrous acid (HNO2) leads to the generation of the nitroalkene derivatives also called NO2-FA. Electrophilic substitution at the double bond mediated by nitronium cation (NO2+) also yields NO2-FA.
Fig. 3Proposed structures for nitro-oleic (NO2-OA) and nitro-linoleic acids (NO2-LA), with assignment of their different positional isomers, which were previously detected in in vitro studies and/or biological samples.
Fig. 4Proposed structures for nitro arachidonic acid (NO2-AA), with assignment of its different positional isomers, which were previously detected in in vitro studies and/or biological samples.
Fig. 5Proposed structures for nitro-docosahexaenoic acid (NO2-DHA), with assignment of its different positional isomers, which were previously detected in in vitro studies and/or biological samples.
Nitro-fatty acids identified in biological samples and in vitro mimetic model systems.
| NO2-OA | 9-NO2-OA | Gastric juice artificial + NO2− | C18-HPLC-ESI-MS and MS/MS in a API 4000 triple quadrupole and LTQ Orbitrap Velos | |
| 10-NO2-OA | ||||
| Pancreatic lipase-digested EVOO | ||||
| NO2-OA | MPO + H2O2 + NO2− | C18-HPLC-ESI-MS and MS/MS in a hybrid triple quadrupole-linear ion trap (4000 Q-Trap) | ||
| ONOO− | ||||
| NO2− in acidic conditions | ||||
| NO2-OA | 9-NO2-OA | ●NO2 | C18-HPLC-ESI-MS and MS/MS in API 2000 triple quadrupole | |
| 10-NO2-OA | ||||
| NO2-LA | 9-NO2-LA | Gastric juice artificial + NO2− | C18-HPLC-ESI-MS and MS/MS in an API 4000 triple quadrupole and LTQ Orbitrap Velos | |
| 10-NO2-LA | ||||
| 12-NO2-LA | Pancreatic lipase-digested EVOO | |||
| 13-NO2-LA | ||||
| NO2-LA | NO2− in acidic conditions | C18-HPLC-ESI-MS and MS/MS in a Quattro triple quadrupole | ||
| NO2-cLA | 8-NO2-cLA | Gastric juice artificial + NO2− | C18-HPLC-ESI-MS and MS/MS in an API 4000 triple quadrupole and LTQ Orbitrap Velos | |
| 9-NO2-cLA | ||||
| 11-NO2-cLA | Pancreatic lipase-digested EVOO | |||
| 12-NO2-cLA | ||||
| NO2-cLA | 9-NO2-cLA | MPO + H2O2 + NO2− | C18-HPLC-ESI-MS and MS/MS in an API 5000 triple quadrupole, API Q-Trap 4000, and Velos Orbitrap | |
| ONOO− | ||||
| 12-NO2-cLA | ●NO2 | |||
| NO2-cLA | NO2-cLA | Photocontrollable peroxynitrite donor 2,3,5,6-tetramethyl-4- (methylnitrosoamino)phenol (P-NAP) | ESI-MS and MS/MS in a hybrid triple quadrupole-linear ion trap (4000 Q-Trap) | |
| Multiple nitro, nitroso, and nitroxidized derivatives | ||||
| Chol-NO2-LA | NO2− in acidic conditions | C18-HPLLC-ESI/MS/MS in a Quattro II triple quadrupole | ||
| Chol-NO2-LA | NO2− in acidic conditions | ESI–MS and MS/MS in a 2000 Q-Trap | ||
| C18-HPLC-ESI–MS and MS/MS in a 2000 Q-Trap | ||||
| NO2-AA | ●NO2 | C18-HPLC-ESI-MS and MS/MS in an Esquire ion trap | ||
| NO2-AA | 9-NO2-AA | NO2− in acidic conditions | C18-HPLC-ESI-MS and MS/MS in a hybrid quadrupole-linear ion trap | |
| 12-NO2-AA | ||||
| 14-NO2-AA | ||||
| 15-NO2-AA | ||||
| NO2-POA | Human plasma and urine | C18-HPLC-ESI-MS and MS/MS in a hybrid triple Q-linear ion trap (4000 Q-Trap) | ||
| NO2OH-POA | Human plasma and urine | C18-HPLC-ESI-MS and MS/MS in a hybrid triple Q-linear ion trap (4000 Q-Trap) | ||
| NO2-OA | Human red cells, plasma and urine | C18-HPLC-ESI-MS and MS/MS in a hybrid triple Q-linear ion trap (4000 Q-Trap) | ||
| NO2-OA | 9-NO2-OA | Myocardial heart tissue from a murine model of focal myocardial ischemia/reperfusion | C18-HPLC-ESI MS/MS | |
| 10-NO2-OA | ||||
| NO2-OA | NO2-OA and β-oxidation metabolites | NO2-OA acute intravenous treatment of mice with LPS-induced inflammation | C18-HPLC-ESI-MS/MS in an API 5000 triple quadrupole | |
| NO2-OA | NO2-OA and its metabolic derivatives | Human and rat urine after intravenous administration of NO2-OA | C18-HPLC-ESI-MS and MS/MS in a LTQ Velos Orbitrap and API 5000 triple quadrupole | |
| NO2-OA | NO2-OA and its metabolic derivatives | Mitochondrial extracts from rat hearts after ischemia-reperfusion | BME trans-nitroalkylation + C18-HPLC-ESI-MS and MS/MS in a 4000 Q trap hybrid triple quadrupole-linear ion trap | |
| Dinitro-OA | Rat cardiomyocytes treated with peroxynitrite donor 3- | C18-HPLC-ESI-MS and MS/MS in a hybrid triple quadrupole-linear ion trap (4000 Q-Trap) | ||
| morpholinosydnonimine (SIN-1) | ||||
| NO2-OA | NO2-OA and its Saturation, Desaturation | Plasma from NO2-OA-treated mice | C18-HPLC-ESI MS/MS coupled to an API 4000 hybrid triple quadrupole or API 5000 triple quadrupole | |
| β-oxidation metabolic derivatives | ||||
| NO2-OA | NO2-OA saturation derivatives | NO2-OA-treated BAEC cells | C18-HPLC-ESI MS/MS coupled to an API 4000 hybrid triple quadrupole or API 5000 triple quadrupole | |
| NO2-OA | NO2-OA and its derivatives | Liver lipid extracts from NO2-OA-treated mice | C18-HPLC-ESI MS/MS coupled to an API 4000 hybrid triple quadrupole or API 5000 triple quadrupole | |
| NO2OH-OA | Human red cells, plasma and urine | C18-HPLC-ESI-MS and MS/MS in a hybrid triple Q-linear ion trap (4000 Q-Trap) | ||
| NO2-LA | Myocardial heart tissue from a murine model of focal myocardial ischemia/reperfusion | C18-HPLC-ESI MS and MS/MS | ||
| NO2-LA | Human plasma and urine | C18-HPLC-ESI-MS and MS/MS in a hybrid triple Q-linear ion trap (4000 Q-Trap) | ||
| NO2-LA | Human blood plasma | C18-HPLC-ESI-MS and MS/MS in a Quattro triple quadrupole | ||
| NO2-LA | 9-NO2-LA | Human red cell membranes and plasma | C18-HPLC-ESI-MS and MS/MS in a hybrid triple Q-linear ion trap | |
| 12-NO2-LA | ||||
| NO2-LA | NO2-LA and its metabolic derivatives | Mitochondrial extracts from rat hearts after ischemia-reperfusion | BME trans-nitroalkylation + C18-HPLC-ESI-MS and MS/MS in a 4000 Q trap hybrid triple quadrupole-linear ion trap | |
| NO2OH-LA | Myocardial heart tissue from a murine model of focal myocardial ischemia/reperfusion | C18-HPLC-ESI MS and MS/MS | ||
| NO2OH-LA | Human plasma and urine | C18-HPLC-ESI-MS and MS/MS in a hybrid triple Q-linear ion trap (4000 Q-Trap) | ||
| NO2-oxo-LA | Myocardial heart tissue from a murine model of focal myocardial ischemia/reperfusion | C18-HPLC-ESI MS/MS | ||
| Plasma and vaginal lavages after cLA inoculation in the vaginal lumen from mice infected intravaginally with HSV-2 | C18-HPLC-MS/MS in a 6500+ Q-trap or a API 5000 | |||
| NO2-LNA | Human plasma and urine | C18-HPLC-ESI-MS and MS/MS in a hybrid triple Q-linear ion trap (4000 Q-Trap) | ||
| NO2OH-LNA | Human plasma and urine | C18-HPLC-ESI-MS and MS/MS in a hybrid triple Q-linear ion trap (4000 Q-Trap) | ||
| NO2-AA | Human plasma and urine | C18-HPLC-ESI-MS and MS/MS into a hybrid triple Q-linear ion trap (4000 Q-Trap) | ||
| NO2-AA | Rat cardiomyocytes treated with peroxynitrite donor 3- | C18-HPLC-ESI-MS and MS/MS in a hybrid triple quadrupole-linear ion trap (4000 Q-Trap) | ||
| morpholinosydnonimine (SIN-1) | ||||
| NO2OH-AA | Human plasma and urine | C18-HPLC-ESI-MS and MS/MS in a hybrid triple Q-linear ion trap (4000 Q-Trap) | ||
| NO2-EPA | Human plasma and urine | C18-HPLC-ESI-MS and MS/MS in a hybrid triple Q-linear ion trap (4000 Q-Trap) | ||
| NO2OH-EPA | Human plasma and urine | C18-HPLC-ESI-MS and MS/MS in a hybrid triple Q-linear ion trap (4000 Q-Trap) | ||
| NO2-DHA and dinitro-DHA | Rat cardiomyocytes treated with peroxynitrite donor 3- | C18-HPLC-ESI-MS and MS/MS in a hybrid triple quadrupole-linear ion trap (4000 Q-Trap) | ||
| morpholinosydnonimine (SIN-1) | ||||
| NO2OH-DHA | Rat cardiomyocytes treated with peroxynitrite donor 3- | C18-HPLC-ESI-MS and MS/MS in a hybrid triple quadrupole-linear ion trap (4000 Q-Trap) | ||
| morpholinosydnonimine (SIN-1) | ||||
| NO2OH-DPA | Rat cardiomyocytes treated with peroxynitrite donor 3- | C18-HPLC-ESI-MS and MS/MS in a hybrid triple quadrupole-linear ion trap (4000 Q-Trap) | ||
| Morpholinosydnonimine (SIN-1) | ||||
| NO2-cLA | 9-NO2-cLA | Pancreatic lipase-digested EVOO | C18-HPLC-ESI-MS and MS/MS in an API 4000 triple quadrupole and LTQ Orbitrap Velos | |
| 12-NO2-cLA | ||||
| NO2-cLA | 9-NO2-cLA | Urine of healthy humans | C18-HPLC-ESI-MS and MS/MS in a LTQ Velos Orbitrap and AB 5000 or API4000 Q-trap triple quadrupole | |
| 12-NO2-cLA | ||||
| β-oxidation-metabolic derivatives of NO2-cLA | ||||
| NO2-cLA | 9-NO2-cLA | Rodents urine, plasma, and tissues (stomach, small intestine, colon, liver) after supplementation with cLA + NO2− and gastric acidification | C18-HPLC-ESI-MS and MS/MS in an API 5000 triple quadrupole, API Q-Trap 4000, and Velos Orbitrap | |
| Rodents liver and cardiac mitochondria incubated with NO2− in acidic conditions | ||||
| 12-NO2-cLA | ||||
| Rodents cardiac tissue under ischemia-reperfusion | ||||
| Raw 264.7 macrophages stimulated with LPS/IFN | ||||
| Healthy human plasma | ||||
| NO2-cLA | 9-NO2-cLA | RAW264.7 macrophages stimulated with LPS/IFN | C18-HPLC-ESI-MS and MS/MS in an API 5000 or a Q-Trap 6500+ and LTQ Velos Orbitrap | |
| 12-NO2-cLA | ||||
| Reduction and β-oxidation-metabolic derivatives | ||||
| Mice Peritoneal exudates after zymosan-A induced peritonitis | ||||
| and cLA supplementation | ||||
| NO2-cLA | NO2-cLA and β-oxidation-metabolic derivatives | Urine and plasma healthy humans after ingestion of nitrite, nitrate and cLA | C18-HPLC-ESI-MS and MS/MS in a 5000 triple quadrupole | |
| Chol-NO2-LA | Human blood plasma and lipoproteins from normolipidemic/healthy subjects | C18-HPLLC-ESI/MS/MS in a Quattro II triple quadrupole | ||
| Chol-NO2-LA | J774.1 macrophages timulated with LPS/IFN | C18-HPLC-ESI–MS and MS/MS in a 2000 Q-Trap | ||
Modulation of target signaling pathways by NO2-FA and related biological properties.
NF-kB ↓ TL4R signaling ↓ PG H synthase ↓ 5-LOX ↓ STAT1 ↓ Cytokine production ↓ MPO ↓ Leukocyte recruitment, adhesion and infiltration ↓ iNOS ↓ COX-2 ↓ PGE2 ↓ Leukocytes number and activity ↓ TNF-α ↓ Xanthine oxidoreductase (XOR) ↓ MKP-1 ↑ PPARγ ↑ TRPA-1 ↑ CD36 expression ↑ Heme oxygenase 1 (HO-1) ↑ STING ↓ PDI ↓ NADPH oxidase (NOX 2) ↓ |
Nitric oxide ↑ eNOS ↑ Ang II-induced vasoconstriction ↓ |
Lipid peroxidation ↓ Nrf2 ↑ HO-1 ↑ Reduction of protein nitration and oxidation Heat shock response (HSP) proteins XOR ↓ NOX 2 ↓ O2●-, ONOO- and NO production ↓ |
AT1R ↓ sEH ↓ Smooth muscle cell proliferation ↓ Prostaglandin F2↓ Differentiation of myofibroblast through Smad2 ↓ |
PPARγ ↑ Glucose uptake ↑ Insulin sensitivity ↑ |
Platelets activation and clotting ↓ Platelet production of thromboxane↓ Thrombin-induced aggregation ↓ PGHS ↓ |
ANT1 ↑ UCP-2 ↑ Mitochondrial dysfunction ↓ Mitochondrial respiratory complex ↑ Metabolic shift ↑ |
Tumor cell proliferation, migration and invasion↓ |
Nitro-fatty acids lipoxidation adducts identified in biological samples and in vitro mimetic model systems by using mass spectrometry-based approaches.
| Cysteine | Incubation of NO2-OA and cysteine | C18-HPLC-MS and MS/MS in a triple quadrupole API 4000 | |||
| Incubation of NO2-OA and cysteine | C18-HPLC-MS and MS/MS in a triple quadrupole | ||||
| Whole olives, mesocarp and peel | C18-HPLC-MS and MS/MS in a triple quadrupole API 4000 | ||||
| GSH | NO2-OA-Cys adduct generation after incubation between NO2-OA and GSH | BME trans-nitroalkylation + C18-HPLC-ESI-MS and MS/MS in a Q trap 4000 | |||
| NO2-OA-Cys adduct generation after incubation between NO2-OA and GSH | (BME trans-nitroalkylation +) C18-HPLC-ESI-MS and MS/MS in a hybrid triple quadrupole API 4000 or API 5000 triple quadrupole | ||||
| Plasma from NO2-OA-treated mice | (BME trans-nitroalkylation) C18-HPLC-ESI-MS and MS/MS in a hybrid triple quadrupole API 4000 or API 5000 triple quadrupole | ||||
| NO2-OA-Cys adduct generation after incubation between NO2-OA and GSH | ESI-MS in LCQ ion trap | ||||
| Tryptic digestion + C18-HPLC-ESI-MS and MS/MS in an ESI-LCQ ion trap | |||||
| C18-HPLC-ESI-MS/MS in a Q-Trap 4000 | |||||
| Red blood cells obtained from healthy humans | C18-HPLC-ESI-MS/MS in a Q-Trap 4000 | Translocation to membrane | Regulation of enzyme function, cell signaling, and protein trafficking | ||
| GAPDH | Cytosolic and membrane-associated protein fractions from red blood cells obtained from healthy humans | SDS-PAGE under non-reducing and denaturing conditions + Tryptic digestion + C18-nanospray LC-MS and MS/MS in a LTQ ion trap | Translocation to membrane | Regulation of enzyme function, cell signaling, and protein trafficking | |
| Cys149 | |||||
| His303 | |||||
| GAPDH | Incubation of NO2-OA and GAPDH | MALDI-TOF MS (Voyager DE PRO system) | |||
| Cys149 | |||||
| C18-HPLC-MS in a LTQ ion trap | |||||
| Cys153 | |||||
| Tryptic digestion and MALDI-TOF MS (Voyager DE PRO system) | |||||
| Cys244 | |||||
| His108 | |||||
| Tryptic digestion + C18-HPLC-ESI-MS in an ESI-LCQ ion trap | |||||
| His134 | |||||
| His327 | Tryptic digestion + C18-nanospray LC-MS and MS/MS in a LTQ ion trap | ||||
| GAPDH | Incubation of NO2-OA and GAPDH | Electrophoresis under reducing conditions + BME trans-nitroalkylation + C18-HPLC-ESI-MS and MS/MS in a 4000 Q trap hybrid triple quadrupole-linear ion trap | |||
| 5-LOX | Incubation of NO2-OA and human recombinant 5-LOX | Tryptic digestion and C18-nanoHPLC-ESI-MS and MS in an Orbitrap XL | Irreversible inhibition of 5-LOX activity and | Anti-inflammatory | |
| Cys416 | |||||
| His125 | |||||
| His360 | Incubation of NO2-OA and human polymorphonuclear leukocytes (PMNL) (intact and cell lysates) | ||||
| Prevention of lung injury and systemic immune responses | |||||
| His362 | |||||
| His367 | |||||
| His372 | NO2-OA treatment in murine model of LPS-induced inflammation (lung injury and cellular infiltration) | ||||
| His432 | |||||
| Keap1 | Incubation of NO2-OA and recombinant Keap1 | Tryptic digestion C18-HPLC-MS and MS/MS in a LTQ | Release of Nrf2 tracsription factor to the nucleous for induction of expression of antioxidant phase II enzymes | Antioxidant | |
| Cys38 | |||||
| Cys151 | |||||
| Cys226 | |||||
| Human embryonic kidney (HEK)-293T cells transfected with recombinant Keap1 and treated with NO2-OA | |||||
| Cys257 | |||||
| Cys489 | |||||
| Catephsin S | Incubation of NO2-OA with a synthetic Cat S peptide (Cat S23–29) | C18-HPLC-MS and MS/MS in a Q Exactive Hybrid Quadrupole-Orbitrap | Downregulation of Cat S expression and activity | Tissue Protection | |
| (Cat S) | |||||
| Anti-inflammatory | |||||
| Cys25 | |||||
| Fp subunit of mitochondrial complex II | Incubation of NO2-OA with recombinant human complex II Fp subunit | Tryptic digestion and C18-HPLC-MS and MS/MS in a LTQ-XL | Inhibition of mitochondrial respiration complex II and O2●− production | Cytoprotective | |
| His2 | |||||
| His5 | |||||
| His6 | |||||
| Rat heart mitochondria treated with OA-NO2 | Blue native electrophoresis, BME trans-nitroalkylation, C18-HPLC-MS amd MS/MS in a hybrid triple-quadrupole linear ion trap mass spectrometer (4000 Q trap) | Promotion of glycolysis | Antioxidant | ||
| Cys9 | |||||
| Cys14 | |||||
| AT1R | HEK293 cells overexpressing AT1R treated with NO2-OA | Immunoprecipitation of AT1R from cell lysates, BME trans-nitroalkylation reaction of AT1R-bound NO2-OA, and C18-HPLC-MS and MS/MS in a 4000 Q-Trap triple quadrupole | Inhibits AT1R-dependent vasoconstriction by reduction of heterotrimeric G-protein coupling and inhibition of IP3 and calcium mobilization | Anti-hypertensive | |
| MMP-7 | Incubation of NO2-OA with recombinant human proMMP-7 and proMMP-9 | C18-HPLC-ESI-MS and MS/MS in a LTQ-XL | Modulation of proteolytic activity | Anti-inflammatory | |
| Cys70 | |||||
| C18-HPLC-ESI-MS and MS/MS in a hybrid triple quadrupole-linear ion trap 4000 Q-Trap | Decrease of enzyme expression | ||||
| MMP-9 | |||||
| Cys100 | |||||
| Albumin | Plasma from intraperitoneal NO2-OA-treated mice | Electrophoresis under reducing conditions + BME trans-nitroalkylation + C18-HPLC-ESI-MS and MS/MS in a 4000 Q trap hybrid triple quadrupole-linear ion trap | |||
| Plasma from NO2-OA-treated mice | Electrophoresis + BME trans-nitroalkylation + C18-HPLC-ESI-MS and MS/MS in a hybrid triple quadrupole API 4000 or API 5000 triple quadrupole | ||||
| PPARγ | Incubation of NO2-OA with human recombinant PPARγ LBD | Tryptic digestion and C18-HPLC-MS and MS/MS in a LTQ | Activation of PPARγ-related gene expression for glucose regulation and adipogenesis | Anti-hyperglycemic | |
| HEK 293 T cells were transfected with PPARγ and treated with NO2-OA | Immunoprecipitation, gel electrophoresis, BME- trans-nitroalkylation and ESI-MS and MS/MS in a hybrid triple quadrupole-linear ion trap mass spectrometer (4000 Q Trap, | Decrease in adipogenesis | |||
| Increase glucose uptake | Anti-adipogenic effect | ||||
| His266 | |||||
| His323 | Restore insulin sensivity | ||||
| His425 | |||||
| His449 | |||||
| STING | Incubation human STING-transfected HEK293T cells with 10-NO2-OA | Purification with magnetic beads, tryptic digestion and MALDI LTQ | Deregulation of STING palmitoylatio | Anti-inflammatory | |
| Cys88 | |||||
| Inhibition of STING signaling | |||||
| Cys91 | Orbitrap XL | Inhibition the release of type I IFN | |||
| His16 | |||||
| cysteine | NO2-LA-Cys adduct generation after incubation between NO2-LA and cysteine | (C18-HPLC)-ESI-MS and MS/MS in a triple quadrupole | |||
| GSH | NO2-LA-Cys adduct generation after incubation between NO2-LA and GSH | ESI-MS in LCQ ion trap | |||
| C18-HPLC-ESI-MS/MS in a Q-Trap 4000 | |||||
| NO2-LA-Cys adduct generation after incubation between NO2-LA and GSH | BME trans-nitroalkylation + C18-HPLC-ESI-MS and MS/MS in a Q trap 4000 | ||||
| NO2-LA-Cys adduct | C18-HPLC/ESI/MS in Micromass Quattro II triple quadrupole | ||||
| Generation after incubation between NO2-LA and GSH | |||||
| Red blood cells obtained from healthy humans | C18-HPLC-ESI-MS/MS in Q-Trap 4000 | ||||
| MCF7/WT and MCF7/MRP1–10 cells treated with NO2-LA | C18-HPLC/ESI/MS in Micromass Quattro II triple quadrupole | ||||
| ANT1 | NO2-LA-treated intact perfused hearts | Immunoprecipitation + SDS-PAGE + in-gel digestion tryptic digestion + ABSciex 5800 MALDI-TOF-TOF MS and MS/MS | Mitochondrial uncoupling | Cytoprotective | |
| Cys57 | |||||
| cysteine | NO2-cLA-Cys adduct generation after incubation between NO2-cLA and cysteine | C18-HPLC-MS and MS/MS in LTQ Velos Orbitrap and AB 5000 or API4000 Q-trap triple quadrupole | |||
| Urine from healthy humans | C18-HPLC-MS and MS/MS in LTQ Velos Orbitrap and AB 5000 or API 4000 Q-trap triple quadrupole | ||||
| NO2-cLA-Cys adduct generation after incubation between NO2-cLA and cysteine | C18-HPLC-MS and MS/MS in API 5000 triple quadrupole | ||||
| Urine from healthy humans | C18-HPLC-MS and MS/MS in API 5000 triple quadrupole | ||||
| PDI | Incubation of human recombinat PDI with NO2-AA | C4-HPLC-MS of intact protein in a hybrid triple quadrupole/linear ion trap mass spectrometer (Q-trap 4500) | Inhibition of reductase and chaperone activity of PDI | Anti-inflammatory | |
| digestion tryptic digestion and C18-HPLC-MS and MS/MS | |||||
| Cys397 | |||||
| Cys400 | |||||
Fig. 6ESI-MS spectra of mono charged [M+H]+ (A) and double charged [M+ 2H]2+ ions (B) of NO2POPC-GSH adducts, acquired in Q-Exactive Orbitrap, with identification of major fragmentation pathways. (Reprinted with permission from [49], copyright 2018 [John Wiley & Sons]).